NCT06507371View on ClinicalTrials.gov

Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

February 15, 2026

Study Completion Date

August 15, 2026

Conditions
Rectal Cancer
Interventions
RADIATION

node-sparing modified short-course radiotherapy

radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes: 25Gy/5Fx

DRUG

PD-1 antibody

PD-1 antibody (Tislelizumab): 200mg d1 q3w

DRUG

Capecitabine

Capecitabine: 1000mg/m2 d1-14 q3w

DRUG

Oxaliplatin

Oxaliplatin: 130mg/m2 d1 q3w

RADIATION

standard short-course radiotherapy

radiation targeting the tumor bed and surrounding tumor-draining lymph nodes: 25Gy/5Fx

Trial Locations (1)

310016

RECRUITING

Sir Run Run Shao hospital, Hanzhou

All Listed Sponsors
lead

Sir Run Run Shaw Hospital

OTHER